Geode Capital Management LLC raised its holdings in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) by 10.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 398,856 shares of the company’s stock after purchasing an additional 36,405 shares during the period. Geode Capital Management LLC owned 1.05% of SCYNEXIS worth $594,000 at the end of the most recent reporting period.
Separately, Acadian Asset Management LLC raised its position in SCYNEXIS by 28.4% during the 2nd quarter. Acadian Asset Management LLC now owns 540,683 shares of the company’s stock valued at $1,080,000 after purchasing an additional 119,600 shares during the last quarter. 54.37% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised SCYNEXIS from a “sell” rating to a “hold” rating in a research report on Friday, November 8th.
SCYNEXIS Stock Performance
Shares of NASDAQ:SCYX opened at $1.23 on Friday. SCYNEXIS, Inc. has a 52-week low of $0.90 and a 52-week high of $3.07. The firm has a market capitalization of $46.68 million, a P/E ratio of -1.66 and a beta of 1.53. The stock has a 50 day moving average price of $1.21 and a 200-day moving average price of $1.53.
SCYNEXIS (NASDAQ:SCYX – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14. SCYNEXIS had a negative return on equity of 66.21% and a negative net margin of 425.41%. The firm had revenue of $0.66 million during the quarter. On average, equities analysts forecast that SCYNEXIS, Inc. will post -0.55 EPS for the current fiscal year.
About SCYNEXIS
SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Further Reading
- Five stocks we like better than SCYNEXIS
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- The Risks of Owning Bonds
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Want to see what other hedge funds are holding SCYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report).
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
